GlycoMimetics sets terms for IPO – Fortune

According to Fortune, GlycoMimetics has set its previously announced IPO to 4 million shares priced between $14 and $16 per share. The company plans to list the stock on the NASDAQ under the ticker symbol “GLYC.” Jefferies and Barclays are the lead underwriters. Based in Gaithersburg, MD, GlycoMimetics is a biotech company focused on developing glycomimetic drugs. It is backed by New Enterprise Associates, Genzyme Ventures, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures.